Posted by Michael Wonder on 29 Nov 2023
Belzutifan for the treatment of patients with a tumour associated with von Hippel-Lindau disease
29 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of belzutifan in the NHS in England.
For the time being, belzutifan is not recommended for the treatment of adults with von Hippel-Lindau (VHL) disease who need treatment for VHL associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumours, and when localised procedures are unsuitable or undesirable.
